
    
      This is a double blind, randomized, active controlled, phase 3 study. Subjects will be
      randomly assigned to one of the three treatment groups (CJ-12420 50mg, CJ-12420 100mg,
      esomeprazole 40mg).

      All subjects will be asked to take three tablets at the same time each day throughout the
      study, and also all subjects will be asked to record daytime and nighttime symptom in a
      subject diary on a daily basis.
    
  